Actively Recruiting
Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
Led by UMC Utrecht · Updated on 2025-12-18
40
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
U
UMC Utrecht
Lead Sponsor
S
Sanofi
Collaborating Sponsor
AI-Summary
What this Trial Is About
With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.
CONDITIONS
Official Title
Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients with moderate-to-severe prurigo nodularis starting dupilumab treatment
You will not qualify if you...
- Unwilling to participate in the BioDay registry
- Unwilling to participate in UMC Utrecht Biobank (for translational endpoints only)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University Medical Center Utrecht
Utrecht, Utrecht, Netherlands
Actively Recruiting
Research Team
M
Marjolein de Bruin-Weller, Professor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here